<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37012059</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000875</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000875</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a novel and simple SLE disease activity instrument, consisting of a tandem clinician-reported (ClinRO) and patient-reported (PRO) outcome measure. The aim of this study was to compare the LFA-REAL system with other SLE activity measures in the phase III trial of ustekinumab in patients with active SLE.</AbstractText><AbstractText Label="METHODS">This was a prespecified analysis of data from a randomised, double-blind, placebo-controlled, parallel-group trial conducted at 140 sites in 20 countries. Correlations were evaluated between the LFA-REAL ClinRO and PRO with a panel of clinician-reported and patient-reported disease activity measures commonly used in SLE clinical trials at baseline, week 24 and week 52. All p values are reported as nominal.</AbstractText><AbstractText Label="RESULTS">Trial participants included 516 patients with SLE with a mean (SD) age of 43.5 (8.9), of whom 482 (93.4%) were female. The LFA-REAL ClinRO correlated with Physician Global Assessment (r=0.39, 0.65 and 0.74, p&lt;0.001), British Isles Lupus Assessment Group Index (r=0.43, 0.67 and 0.73, p&lt;0.001) and SLE Disease Activity Index-2000 (r=0.35, 0.60 and 0.62, p&lt;0.001). The LFA-REAL ClinRO arthralgia/arthritis score correlated well with active joint counts (r=0.54, 0.73 and 0.68, p&lt;0.001) and the mucocutaneous global score correlated strongly with Cutaneous Lupus Erythematosus Disease Area and Severity Index total activity (r=0.57, 0.77 and 0.81, p&lt;0.001). The LFA-REAL PRO demonstrated a moderate correlation with Functional Assessment of Chronic Illness Therapy-Fatigue (r=-0.60, -0.55 and -0.58, p&lt;0.001), Lupus QoL physical health (r=-0.42, -0.47 and -0.46, p&lt;0.001), SF-36v2 vitality (r=-0.40, -0.43 and -0.58, p&lt;0.001) and SF-36v2 Physical Component Summary (r=-0.45, -0.53 and -0.53, p&lt;0.001). The LFA-REAL ClinRO and PRO showed a moderate correlation with each other (r=0.32, 0.45 and 0.50, p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The LFA-REAL ClinRO and PRO showed varied levels of correlations (weak to strong) with existing physician-based lupus disease activity measures and patient-reported outcome instruments, respectively and were able to more accurately capture organ-specific mucocutaneous and musculoskeletal manifestations. More analyses are needed to determine areas in which patient-reported outcomes are most similar or different to physician-reported end points and the basis for differences.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Askanase</LastName><ForeName>Anca D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4597-5023</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Columbia University Irving Medical Center, New York City, New York, USA ada20@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medicine, Westchester Medical Center, Valhalla, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuraw</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Clinical Development Immunology, Janssen Research and Development LLC, Spring House, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Data Science, IQVIA Inc, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brotherton</LastName><ForeName>Betsy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Data Science, IQVIA Inc, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Joan T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Arthritis &amp; Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>FU77B4U5Z0</RegistryNumber><NameOfSubstance UI="D000069549">Ustekinumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069549" MajorTopicYN="Y">Ustekinumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">arthritis</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">outcome assessment, health care</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37012059</ArticleId><ArticleId IdType="pmc">PMC10083883</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000875</ArticleId><ArticleId IdType="pii">10/1/e000875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929&#x2013;39. 10.1056/NEJMra071297</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Merrill JT. Measuring disease activity in SLE is an ongoing struggle. Nat Rev Rheumatol 2019;15:194&#x2013;5. 10.1038/s41584-019-0190-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0190-1</ArticleId><ArticleId IdType="pubmed">30804539</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Bruce IN, Gordon C, et al. . Current challenges in the development of new treatments for lupus. Ann Rheum Dis 2019;78:729&#x2013;35. 10.1136/annrheumdis-2018-214530</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214530</ArticleId><ArticleId IdType="pubmed">30636212</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Petri MA, Kim MY, et al. . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142(12 Pt 1):953&#x2013;62. 10.7326/0003-4819-142-12_part_1-200506210-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-142-12_part_1-200506210-00004</ArticleId><ArticleId IdType="pubmed">15968009</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550&#x2013;8. 10.1056/NEJMoa051135</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Rahman A, Allen E, et al. . BILAG 2004. development and initial validation of an updated version of the British Isles lupus assessment group&#x2019;s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902&#x2013;6. 10.1093/rheumatology/keh624</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus D, Rodrigues M, Matos A, et al. . Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients. Lupus 2019;28:607&#x2013;12. 10.1177/0961203319836717</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319836717</ArticleId><ArticleId IdType="pubmed">30895904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee C-S, Farewell VT, Isenberg DA, et al. . The use of systemic lupus erythematosus disease activity index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011;50:982&#x2013;8. 10.1093/rheumatology/keq376</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq376</ArticleId><ArticleId IdType="pmc">PMC3077910</ArticleId><ArticleId IdType="pubmed">21245073</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Merrill JT. Top 10 things to know about lupus activity measures. Curr Rheumatol Rep 2013;15:334. 10.1007/s11926-013-0334-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-013-0334-2</ArticleId><ArticleId IdType="pubmed">23606072</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranow C, Askanase A, Oon S, et al. . Laboratory investigation results influence physician&#x2019;s global assessment (PGA) of disease activity in SLE. Ann Rheum Dis 2020;79:787&#x2013;92. 10.1136/annrheumdis-2019-216753</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216753</ArticleId><ArticleId IdType="pubmed">32241797</ArticleId></ArticleIdList></Reference><Reference><Citation>Chessa E, Piga M, Floris A, et al. . Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford) 2020;59:3622&#x2013;32. 10.1093/rheumatology/keaa383</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa383</ArticleId><ArticleId IdType="pubmed">32789462</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Petri MA, Wallace DJ, et al. . Novel evidence-based systemic lupus erythematosus Responder index. Arthritis Rheum 2009;61:1143&#x2013;51. 10.1002/art.24698</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24698</ArticleId><ArticleId IdType="pmc">PMC2748175</ArticleId><ArticleId IdType="pubmed">19714615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Kalunian K, Petri MA, et al. . Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183&#x2013;90. 10.1136/annrheumdis-2012-202760</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202760</ArticleId><ArticleId IdType="pmc">PMC3888603</ArticleId><ArticleId IdType="pubmed">23313811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Strand V, Furie R, et al. . Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the british isles lupus assessment group-based composite lupus assessment endpoint. Arthritis Rheumatol 2011;63:S885&#x2013;6.</Citation></Reference><Reference><Citation>van Vollenhoven R, Voskuyl A, Bertsias G, et al. . A framework for remission in SLE: consensus findings from a large international Task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554&#x2013;61. 10.1136/annrheumdis-2016-209519</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;75:1615&#x2013;21. 10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong KP, Chong EYY, Kong KO, et al. . Discordant assessment of lupus activity between patients and their physicians: the Singapore experience. Lupus 2010;19:100&#x2013;6. 10.1177/0961203309345748</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309345748</ArticleId><ArticleId IdType="pubmed">19880553</ArticleId></ArticleIdList></Reference><Reference><Citation>Elera-Fitzcarrald C, Vega K, Gamboa-C&#xe1;rdenas RV, et al. . Discrepant perception of lupus disease activity: a comparison between patients&#x2019; and physicians&#x2019; disease activity scores. J Clin Rheumatol 2020;26(7S Suppl 2):S165&#x2013;9. 10.1097/RHU.0000000000001267</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001267</ArticleId><ArticleId IdType="pubmed">31895090</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, James JA, Arriens C, et al. . Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med 2019;6:e000365. 10.1136/lupus-2019-000365</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000365</ArticleId><ArticleId IdType="pmc">PMC6937422</ArticleId><ArticleId IdType="pubmed">31921432</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Daly RP, Okado M. Development and content validity of the lupus foundation of america rapid evaluation of activity in lupus (LFA-realdevelopment and content validity of the lupus foundation of america rapid evaluation of activity in lupus (LFA-REALTM): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes 2019;17:99. 10.1186/s12955-019-1151-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-019-1151-8</ArticleId><ArticleId IdType="pmc">PMC6555910</ArticleId><ArticleId IdType="pubmed">31174541</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase A, Li X, Pong A, et al. . Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med 2015;2:e000075. 10.1136/lupus-2014-000075</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000075</ArticleId><ArticleId IdType="pmc">PMC4378376</ArticleId><ArticleId IdType="pubmed">25861457</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Kalunian KC, D&#xf6;rner T, et al. . Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis 2022;81:1556&#x2013;63. 10.1136/ard-2022-222858</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222858</ArticleId><ArticleId IdType="pmc">PMC9606504</ArticleId><ArticleId IdType="pubmed">35798534</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee C-S, Cresswell L, Farewell V, et al. . Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 2010;49:1665&#x2013;9. 10.1093/rheumatology/keq026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keq026</ArticleId><ArticleId IdType="pmc">PMC2919194</ArticleId><ArticleId IdType="pubmed">20181671</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Nguyen SC, Costenbader K, et al. . Comparison of the lupus Foundation of america-rapid evaluation of activity in lupus to more complex disease activity instruments as evaluated by clinical Investigators or real-world clinicians. Arthritis Care Res (Hoboken) 2018;70:1058&#x2013;63. 10.1002/acr.23445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23445</ArticleId><ArticleId IdType="pubmed">28992399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Gamboa-Cardenas RV, Re&#xe1;tegui-Sokolova C, et al. . Evaluation of the LFA-REAL clinician-reported outcome (clinro) and patient-reported outcome (pro): data from the Peruvian almenara lupus cohort. Lupus Sci Med 2020;7:e000419. 10.1136/lupus-2020-000419</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000419</ArticleId><ArticleId IdType="pmc">PMC7552838</ArticleId><ArticleId IdType="pubmed">33046557</ArticleId></ArticleIdList></Reference><Reference><Citation>Elefante E, Tani C, Signorini V, et al. . Evaluation of the lupus foundation of america-rapid evaluation of activity in lupus as a measure of systemic lupus erythematosus (SLE) disease activity from the clinician and the patient perspective: experience from an italian cohort. Arthritis Rheumatol 2020;72 Suppl 10:1&#x2013;4231. 10.1002/art.41538</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41538</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, McGwin G, Brooks K, et al. . Systemic lupus erythematosus in three ethnic groups. XI. sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. Arthritis Rheum 2002;47:408&#x2013;13. 10.1002/art.10512</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10512</ArticleId><ArticleId IdType="pubmed">12209488</ArticleId></ArticleIdList></Reference><Reference><Citation>Neville C, Clarke AE, Joseph L, et al. . Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 2000;27:675&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10743807</ArticleId></ArticleIdList></Reference><Reference><Citation>Askanase AD, Castrej&#xf3;n I, Pincus T. Quantitative data for care of patients with systemic lupus erythematosus in usual clinical settings: a patient multidimensional health assessment questionnaire and physician estimate of noninflammatory symptoms. J Rheumatol 2011;38:1309&#x2013;16. 10.3899/jrheum.101091</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.101091</ArticleId><ArticleId IdType="pubmed">21459938</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>